Kristine Kucera, PA-C, MPAS, DHS
Adjunct Clinical Instructor
Physician Assistant Studies
University of Texas Southwestern Medical Center
Adjunct Clinical Instructor
University of North Texas Health Science Center
Fort Worth, Texas
Alan Menter, MD
Clinical Professor of Dermatology
University of Texas Southwestern Medical School
Chief, Division of Dermatology
Baylor University Medical Center
This activity will address the management of psoriasis, including setting psoriasis treatment goals and monitoring treatment response to determine when adjustments to therapy are needed; developing tailored, evidence-based treatment regimens for individual patients; engaging patients in shared decision making for improved patient satisfaction; and considering clinical advances while developing treatment regimens for patients with psoriasis.
NPs, PAs, and physicians who are interested in understanding the role of NPs and PAs in the treatment of patients with psoriasis.
Upon completion of this educational activity, the participant should be able to:
- Summarize evidence-based recommendations on setting treatment goals and monitoring response to psoriasis therapy.
- Discuss comorbid conditions, potential treatment responses, and other patient and disease characteristics that can impact psoriasis treatment selection.
- Describe strategies for engaging in shared decision making with patients so that lifelong treatment adherence and patient satisfaction are optimized.
- Review evidence on promising new and investigational treatments and therapeutic strategies that may further improve outcomes in patients with psoriasis.
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices is being discussed.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration.
Dr Kucera: consultant: Eli Lilly and Company, Regeneron Pharmaceuticals, Inc.; speakers bureau: AbbVie Inc., Celgene Corporation, Janssen Global Services, LLC, LEO Pharma Inc., Novartis Pharmaceuticals Corporation, Promius Pharma, LLC, Valeant.
Dr Menter: advisory board: AbbVie Inc., Allergan, Amgen Inc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Janssen Biotech, Inc., LEO Pharma Inc.; consultant: AbbVie Inc., Allergan, Amgen Inc., Eli Lilly and Company, Galderma S.A., Janssen Biotech, Inc., LEO Pharma Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Vitae Pharmaceuticals, Inc., XenoPort, Inc.; investigator: AbbVie Inc., Allergan, Amgen Inc., Anacor Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Celgene Corporation, Dermira, Eli Lilly and Company, Janssen Biotech, Inc., LEO Pharma Inc., Merck & Co., Inc., Neothetics, Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Symbio, LLC/Maruho Co., Ltd., XenoPort, Inc.; speakers bureau: AbbVie Inc., Amgen Inc., Janssen Biotech, Inc., LEO Pharma Inc.
The Planning Committee for this activity included Jody Walker, MS, Julie L. White, MS, and Jason Worcester, MD, of Boston University School of Medicine; Ruth Cohen and Vandana Iyer, PhD, of Practicing Clinicians Exchange; and Paula DiNote, Kathleen Hines, Lily McVey, and Kristen Petro of MCM Education. None of the aforementioned members of the Planning Committee have any significant relationships to disclose.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Practicing Clinicians Exchange. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Boston University School of Medicine designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Course director: Jason Worcester, MD, Boston University School of Medicine.
This activity was jointly provided by MCM Education.
Commercial Support Statements
This activity was supported by an educational grant from Novartis Pharmaceuticals Corporation.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 18.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
Safari 4.0+ for Mac OSX 10.5 and above
After login, please select the following code: NPCE88415
Successful completion of the post-test is required to earn CME credit.
Successful completion is defined as a cumulative score of at least 70%.
Participants wishing to earn CME credit must:
- Listen to the presentation and study the program slides (the estimated time to complete this activity is 1 hour)
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online: www.practicingclinicians.com/testing
The materials presented here do not necessarily reflect the views of MCM Education, Practicing Clinicians Exchange, or companies that provide educational support for programming on practicingclinicians.com. These activities may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should verify all information and data before treating patients or implementing any therapies described in these educational activities. © 2016 MCM Education and Practicing Clinicians Exchange. All Rights Reserved.